

WHO DRUG INFORMATION

Contents

General Policy Topics

Meta-analysis 145

Personal Perspectives

Essential drugs: for patients or for populations? 147

Reports on Individual Drugs

Acetylsalicylic acid in peripheral arterial disease 149

Acute pulmonary embolism: a place for thrombolytic therapy? 150

Venous thromboembolism: heparins – fractionated and unfractionated – in prophylaxis and treatment ... and for how long are anticoagulants really needed? 153

Beta-adrenoreceptor agonists and asthma deaths 153

Pertussis vaccines: cellular and acellular 155

Thiazide therapy: who needs potassium supplements? 156

Magnesium and acute cardiac infarction 158

General Information

More reports of multiresistant *Salmonella typhi* 160

Anti-inflammatory drugs: new insights into adverse gastrointestinal effects 160

Immunity, vitamins and trace elements 161

Regulatory Matters

Stereoisomerism and drug development 163

More on paediatric prescribing in new product labelling 163

Mumps vaccines and meningoencephalitis 164

Non-sedating antihistamines and cardiac arrhythmias 165

Standardized instructions for oral contraceptives 166

Injectable contraceptive approved by FDA 167

Haemodialysis and chronic aluminium poisoning 167

Flucloxacillin: cholestatic jaundice 167

Herbal products: more potential carcinogens 168

Human interleukin-2 for renal cancer 168

Atovaquone for treatment of *Pneumocystis carinii* pneumonia 168

Finasteride for benign prostatic hyperplasia 168

Diethylene glycol: yet another tragedy 169

Consultative Document

Proposed WHO Guidelines for Good Clinical Practice (GCP) for trials on pharmaceutical products 170

Clinical trial protocol 185

Declaration of Helsinki 186

Recent Publications

Infectious disease: an ominous and unpredictable threat 189

Proposed International Non-proprietary Names: List 68

191